Burmester, Gerd R., Rubbert-Roth, Andrea, Cantagrel, Alain, Hall, Stephen, Leszczynski, Piotr, Feldman, Daniel, Rangaraj, Madura J., Roane, Georgia, Ludivico, Charles, Bao, Min, Rowell, Lucy, Davies, Claire and Mysler, Eduardo F. (2016). Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann. Rheum. Dis., 75 (1). S. 68 - 75. LONDON: BMJ PUBLISHING GROUP. ISSN 1468-2060

Full text not available from this repository.

Abstract

Objectives To evaluate the long-term efficacy and safety of subcutaneous (SC) tocilizumab (TCZ) versus intravenous (IV) TCZ, including switching formulations, in patients with rheumatoid arthritis (RA) and inadequate response to disease-modifying antirheumatic drugs (DMARDs). Methods Patients (n=1262) were randomised 1: 1 to receive TCZ-SC 162 mg weekly (qw)+placebo-IV every four weeks (q4w) or TCZ-IV 8 mg/kg q4w+placebo-SC qw in combination with DMARD(s). After a 24-week double-blind period, patients receiving TCZ-SC were re-randomised 11: 1 to TCZ-SC (n=521) or TCZ-IV (TCZ-SCIV, n=48), and patients receiving TCZ-IV were re-randomised 2: 1 to TCZ-IV (n=372) or TCZ-SC (TCZ-IV-SC; n=186). Maintenance of clinical responses and safety through week 97 were assessed. Results The proportions of patients who achieved American College of Rheumatology (ACR) 20/50/70 responses, Disease Activity Score in 28 joints remission and improvement from baseline in Health Assessment Questionnaire Disability Index >= 0.3 were sustained through week 97 and comparable across arms. TCZ-SC had a comparable safety profile to TCZ-IV through week 97, except that injection site reactions (ISRs) were more common with TCZ-SC. Safety profiles in patients who switched were similar to those in patients who received continuous TCZ-SC or TCZ-IV treatment. The proportion of patients who developed anti-TCZ antibodies remained low across treatment arms. No association between anti-TCZ antibody development and clinical response or adverse events was observed. Conclusions The long-term efficacy and safety of TCZ-SC was maintained and comparable to that of TCZ-IV, except for ISRs. Profiles in patients who switched formulations were comparable to those in patients who received TCZ-IV or TCZ-SC. TCZ-SC provides additional treatment options for patients with RA.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Burmester, Gerd R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rubbert-Roth, AndreaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cantagrel, AlainUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hall, StephenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Leszczynski, PiotrUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Feldman, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rangaraj, Madura J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Roane, GeorgiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ludivico, CharlesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bao, MinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rowell, LucyUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Davies, ClaireUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mysler, Eduardo F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-292231
DOI: 10.1136/annrheumdis-2015-207281
Journal or Publication Title: Ann. Rheum. Dis.
Volume: 75
Number: 1
Page Range: S. 68 - 75
Date: 2016
Publisher: BMJ PUBLISHING GROUP
Place of Publication: LONDON
ISSN: 1468-2060
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
MODIFYING ANTIRHEUMATIC DRUGS; INTERLEUKIN-6 RECEPTOR INHIBITION; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; BIOLOGIC AGENTS; PLACEBO; TRIAL; PROFESSIONALS; MONOTHERAPY; PREFERENCESMultiple languages
RheumatologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/29223

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item